Most people think patent litigation is about winning at the courthouse.
In pharma, thats only half the story. The other half is what happens years earlierwhen teams challenge weak or overly broad methods of use claims before they calcify into an expe…
Sue Early, Win Big: The Hidden ROI of Challenging Weak Method-of-Use Drug Patents Read Post »
The 180-Day Exclusivity Trap: Why First-to-File Winners Still Lose Money
In drug development and generic competition, the phrase first-to-file is often treated like a shortcut to value.
File first under the Hatch-Waxman framework, you win 180 days of e…
The 180-Day Exclusivity Trap: Why First-to-File Winners Still Lose Money Read Post »
Most pharma teams treat patent litigation like a cost center. Thats the mistake.
A settlement can be the right outcomebut it shouldnt be your default playbook.
In todays patent landscape, settle too quickly often turns a litigation strategy into a budg…
Most pharma patent fortresses dont fall because the whole wall collapsesthey fall because the weakest brick cracks first.
And in the device spacewhere courts, regulators, and litigants often ask a different set of questions than they do for traditional…
Why Device Patents Crack First: The Weakest Wall in Your Drug’s Patent Fortress Read Post »
The Salt Change Trap: When a New Patent Buys You Nothing
Drug developers love a clean headline: new patent granted. Investors love it toountil the market reality sets in.
Because in pharma, not every new patent is a new deal. Sometimes its a repackagin…
The Salt Change Trap: When a New Patent Buys You Nothing Read Post »
Pediatric exclusivity was supposed to be a safeguard: an extra six months of market protection to encourage drug developers to study children.
But in practice, the six-month fuse is too often a liabilitynot a shield.
Heres the uncomfortable reality: …
The Six-Month Fuse: Why Pediatric Exclusivity Is a Liability, Not a Shield Read Post »
Bausch Health just gave the patent world a reminder: litigation isnt only about winning argumentsits about controlling what the market believes is imminent.
The dispute at the center of the recent rulingBausch Health Companies Inc. v. Sun Pharmaceutica…
BAUSCH HEALTH COMPANIES INC. v. SUN PHARMACEUTICAL INDUSTRIES LTD. Read Post »
Exelixis v. Intas: Patents Dont Just Decide Drug FuturesThey Define Timelines, Incentives, and Who Can Afford to Wait.
Heres why this case matters beyond the courtroom.
The agitation:
When we talk about patent battles, its easy to imagine a binary outc…
Pharma news isnt just about new drugsits often about courtrooms, timing, and the fine print of patent law.
In the latest decision covered by DrugPatentWatch, Amneal Pharmaceuticals LLC v. Alembic Pharmaceuticals Ltd. is a reminder that the when of mark…
Amneal Pharmaceuticals LLC v. Alembic Pharmaceuticals Ltd. Read Post »
Big pharmas routine patent fight is never routine. Its a strategy memo in disguise.
Thats the takeaway from Exelixis, Inc. v. Handa Pharmaceuticals, Inc.a case that may look narrow on the surface (a specific patent, a specific counterparty), but that…
Get new actionable insights and updates from BiotechBlog
